Recent research published in the Journal of Cardiovascular Pharmacology and Therapeutics has revealed that long-term testosterone therapy (TTh) for males who have hypogonadism (or testosterone deficiency) may also help prevent cardiovascular (CV) disease. Testosterone (T) is the main male sex hormone and is responsible for the development of male reproductive tissues—it also encourages muscle, bone, and body hair growth. Males with a testosterone deficiency are at risk for developing osteoporosis, as insufficient levels contribute to weakness and bone loss.
Researchers followed two groups of men for eight years for an observational study to determine whether testosterone therapy had an effect on the risk of cardiovascular disease. The first group had been treated with testosterone therapy for their hypogonadism, while the second group had not. After the eight years, only two men from the first group had died, and neither instance was related to cardiovascular disease.
In contrast, there were 21 deaths in the second group, 19 of which were caused by cardiovascular-related events. This group also saw 26 non-fatal myocardial infarctions or heart attacks, and 30 non-fatal strokes, while the first group experienced none. Based on these results, the team concluded that long-term testosterone therapy for men with hypogonadism may be an effective method to help improve cardiometabolic function and reduce the risk of cardiovascular disease and related events.
These results show that there may be a protective benefit gained when treating hypogonadal males with long-term testosterone therapy, and with further research, it may be utilized to help prevent cardiovascular disease and events, as well as to treat testosterone deficiency.